- Nivolumab combined with S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (CapeOX) showed encouraging efficacy in unresectable advanced or recurrent HER2-negative gastro/gastroesophageal junction (G/GEJ) cancer.
- Almost all patients reduced or delayed their dose because of treatment-related adverse events (TRAEs).
Why this matters
- Chemotherapy may modulate the immune system, which may, in turn, boost the immune effects of nivolumab.
- The study was part 1 of 2. Part 2 will compare nivolumab plus chemotherapy with placebo plus chemotherapy.
- Open-label study at 13 centers in Japan and South Korea (ATTRACTION-4); 39 patients were randomly assigned to receive nivolumab plus SOX or nivolumab plus CapeOX.
- Funding: Ono Pharmaceutical and Bristol-Myers Squibb.
- 95.2% of patients in nivolumab/SOX and 94.4% of patients in nivolumab/CapeOX reduced or delayed chemotherapy because of TRAEs.
- The objective response rate (ORR) was similar in both groups (66.7% in nivolumab/SOX, 70.6% in nivolumab/CapeOX).
- Corresponding ORR was 57.1% and 76.5%, respectively, when assessed centrally.
- Median OS was not reached in any group. Median OS was 13.9 months overall, 11.9 months for the nivolumab/SOX group, and 11.2 months for the nivolumab/CapeOX group.
- Small study.
- Asian population.